Anti-CD138 antibody is fused with IFNα2 at the C-terminus of the Ab heavy chains, a peptide mask that binds theIFNα2 and competes with its interaction with receptor is attached to the C-terminal end of the interferon by a linker that is cleavable by proteases enriched in the tumor microenvironment.
Selective targeting of cancer in a few different indications where CD138 is upregulated on the cell surface. Kills targeted cancer cells while having less overall toxicity in the body compared to recombinant interferons.
